Company Overview

Kenvue Inc. is the world's largest pure-play consumer health company by revenue, generating $15.5 billion in full-year 2024 sales. Formerly Johnson & Johnson's consumer segment, Kenvue successfully spun off and became a public company in May 2023, establishing itself as an independent entity focused on healthcare products. The company operates globally across the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America, serving approximately 1.2 billion people worldwide through their daily rituals and important life moments.

Business Segments

Kenvue's operations are strategically divided into three primary business segments, each focusing on distinct consumer health categories:

Self Care Segment

This segment encompasses products for cough, cold, and allergy relief, pain management, digestive health, smoking cessation, and eye care. Key brands within this segment include Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSL™, Rhinocort, Calpol, and Zyrtec.

Skin Health and Beauty Segment

This segment offers a wide range of products for face and body care, hair care, sun protection, and other specialized skincare. Prominent brands include Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX.

Essential Health Segment

This segment focuses on essential health and hygiene products such as oral care, baby care, women's health, and wound care. Leading brands in this segment are Listerine, Johnson's®, BAND-AID®, Stayfree®, o.b.®, Carefree®, and Desitin Diaper Rash Cream.

Iconic Brand Portfolio

Kenvue boasts an impressive portfolio of iconic, science-backed brands that are widely recommended by healthcare professionals globally. Brands like Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, and Tylenol® are cornerstones of the company's success. Despite operating in a highly fragmented industry with intense competition and evolving consumer preferences, many of Kenvue's brands hold global leadership positions within their respective categories due to their strong brand equity and consumer trust.

Financial Performance (2024)

Full Year 2024 Results (as of December 29, 2024)

- Net Sales: $15.5 billion, an increase of 0.1% year-over-year.

- Organic Sales Growth: 1.5%, with a foreign currency headwind of 1.4%.

- Diluted EPS: $0.54 (compared to $0.90 in the prior year period).

- Adjusted Diluted EPS: $1.14 (compared to $1.29 in the prior year period).

Fourth Quarter 2024 Results (as of December 29, 2024)

- Net Sales: $3.7 billion, a decrease of 0.1%.

- Organic Sales Growth: 1.7%.

- Diluted EPS: $0.15.

- Adjusted Diluted EPS: $0.26.

Key Business Highlights

- Profitability Improvements: For FY'24, the Gross Profit Margin improved by 200 basis points. The company's "Vue Forward" savings initiatives supported increased marketing investments to drive growth.

- Strategic Focus: CEO Thibaut Mongon highlighted that the company met its 2024 profit commitments despite market headwinds. The strategic emphasis remains on leveraging enhanced brand investments to accelerate growth and generate long-term value through profitable expansion, consistent cash flow generation, and disciplined capital allocation.

- Fortune 500 Recognition: Kenvue made its debut on the prestigious Fortune 500 list for the first time since its independence, ranking at number 281 based on its full-year 2024 sales of $15.5 billion.

Market Position and Competition

Kenvue operates within the competitive consumer health sector, facing competition from major global players such as Procter & Gamble, Unilever, and Nestlé. The company effectively leverages its substantial brand equity, diversified product portfolio, and robust research and development capabilities to maintain its leading market position.

Growth Strategy

Kenvue's growth strategy is multifaceted, focusing on expanding its presence in emerging markets, investing in digital transformation to enhance consumer engagement, and developing sustainable product lines to meet evolving consumer demands. CFO Paul Ruh indicated that Kenvue anticipates accelerating performance throughout the year, navigating the dynamic external environment, and driving further productivity and operational efficiencies. These gains are intended to fund planned increases in brand investments.

With its comprehensive portfolio of trusted healthcare brands and a strong global footprint, Kenvue continues to solidify its leadership in the pure-play consumer health market, positioning itself for sustained long-term growth and value creation.